Only roughly so, whytee. Some $1,800 per eye and injection is...

Only roughly so, whytee. Some $1,800 per eye and injection is what I noticed from publicly available sources.

Yet, in the case of OPT it is not the most relevant question, I’d say. At least not today, when instead management‘s ability to wiseley forecast future cash requirements as well as to execute on enrollment targets have to be reevaluated again.

And that‘s the point where we can observe the following:
Only 12 months ago, when we put together all pieces from the last financing round in August 2023, OPT was forecasting an annual cash burn of roughly $US120 MN and pretending to be financed through topline readout in Q3 2024.

Today, OPT is forecasting an annual cash burn of roughly $US180 MN. A whopping increase of 50% which only very difficultly can be explained without raising concerns on management’s ability to properly evaluate the company‘s future needs.

On top, the new enrollment targets (Q2 2024 vs mid 2023 given out 12 months ago) means enrollment proceeds at only half the pace than OPT’s management forecasted in August 2023.

And finally, this lack of speed in enrollment in combination with the massive cost overruns, is what will bring us back to the table only 10-12 months from now for another massive CR of around $US200MN.

Meanwhile, the price of aflibercept for 12 months in the US is the least I‘d currently worry about.